Multiple sclerosis (MS) wears people down in ways that are hard to explain to anyone who hasn't lived it, and fatigue is often the worst part. Red light therapy, also called photobiomodulation, gets pitched as a drug-free way to ease that fatigue, rebuild muscle strength, and calm the inflammation that drives the disease. This review lays out what the human studies actually found, where the evidence is genuinely promising, and where the marketing has run far ahead of the science.
What Red Light Therapy Is (and What It Isn't)
Red light therapy uses low doses of red and near-infrared light, usually in the 600 to 1100 nanometer (nm) range, delivered by LED panels or low-level lasers. The technical name is photobiomodulation, or PBM. The light is not hot enough to burn and does not cut or destroy tissue the way a surgical laser does. Instead, the idea is that certain wavelengths get absorbed inside your cells and nudge them to work better.
The leading theory centers on the mitochondria, the tiny power plants inside nearly every cell. Red and near-infrared light appears to be absorbed by an enzyme called cytochrome c oxidase, part of the chain that makes cellular energy (ATP). When that enzyme picks up the light, cells may produce more energy, release small bursts of signaling molecules, and dial down inflammation. We cover the cellular details in our guide to the science of photobiomodulation.
Here is a distinction that matters a great deal for MS, and one that gets blurred constantly online. There are two completely different things both loosely called "light therapy":
- Photobiomodulation (red light therapy): red and near-infrared light, dosed in joules, aimed at cells and mitochondria. This is what red light panels and therapeutic lasers do.
- Bright light therapy: very bright white light, dosed in lux, shone toward the eyes to reset the body clock. This is the lightbox treatment used for seasonal depression and circadian problems.
These are not the same treatment, they do not work through the same mechanism, and as you will see below, the MS research has tested both. Mixing them up is the single biggest reason people walk away with the wrong impression about what red light can do for MS.
Why Researchers Thought Red Light Might Help MS
MS is an autoimmune disease. The immune system attacks myelin, the fatty insulation around nerve fibers in the brain and spinal cord. That damage slows or scrambles nerve signals and leaves behind scar tissue (the "sclerosis" in the name). The result can be fatigue, weakness, numbness, vision trouble, balance problems, and pain.
Three features of MS made researchers curious about PBM:
- Energy failure. Damaged nerves and overworked muscles in MS show signs of mitochondrial stress. If PBM really does boost mitochondrial output, it might ease fatigue and improve muscle performance. This is the same energy-and-nerve logic explored in the broader research on nerve regeneration and red light.
- Inflammation. MS attacks are driven by inflammatory immune cells. PBM has been shown in the lab to shift cells toward an anti-inflammatory state, which ties into the wider question of whether red light can calm systemic inflammation.
- A drug-free profile. MS disease-modifying drugs are powerful but can carry serious side effects. A safe, at-home option that helped even a little would be welcome.
Those are reasonable hypotheses. The question is whether they hold up when you actually shine the light on real patients. So let's look at the data.
The Human Evidence, Study by Study
The honest summary up front: the human evidence for red light therapy in MS is early, small, and mixed. A few well-run trials exist, but they point in different directions, and none is large enough to change clinical practice. A 2024 systematic review of photobiomodulation for MS in Frontiers in Neurology found only eight studies worth including worldwide, and just four of those were human randomized clinical trials. The other four were animal experiments. That is a thin foundation for a condition that affects nearly a million people in the United States alone.
Photobiomodulation for fatigue: a negative result
Fatigue is the headline claim, so this is the most important study to understand. A 2022 pilot trial published in Lasers in Medical Science tested PBM specifically for fatigue in people with relapsing-remitting MS. Researchers used an 808 nm near-infrared laser delivering 36 joules per session, applied either under the tongue or over the radial artery at the wrist, and measured fatigue with the Modified Fatigue Impact Scale (MFIS), a standard questionnaire.
The result was blunt. As the authors wrote, "photobiomodulation with the parameters employed in the present study had no effect on fatigue in individuals with multiple sclerosis." No meaningful improvement. This single trial does not close the book, because it tested only one dose, one wavelength, and two unusual delivery sites. But it is the most direct test of the core marketing claim, and it came back empty.
Photobiomodulation for muscle function: a partial win
Muscle strength is a different story, and here the news is cautiously better. A 2024 study in Multiple Sclerosis and Related Disorders ran a randomized, double-blind, sham-controlled crossover design, the gold standard for ruling out placebo effects. Researchers applied PBM (600 to 1100 nm) to the tibialis anterior, a shin muscle, at doses of 40, 80, and 120 joules.
After two weeks of individualized dosing, the active treatment produced significant gains in muscle strength and force recovery compared with the sham. The authors concluded that "an individualized dose of PBMT might improve muscle performance, including force recovery and strength in individuals with mild-moderate MS." Importantly, the same study found no improvement in muscle endurance or fatigue resistance. So even the positive trial supports a narrow claim about strength and recovery, not the broad "fixes MS fatigue" promise. The sample sizes were also tiny, 17 people in one arm and 12 in another.
"Light therapy" trials that actually argue against red light
Now the nuance that catches almost everyone. Two of the four human trials counted in the MS literature tested bright white light for fatigue, not red light therapy. And they built their experiments in a way that, read carefully, is a strike against dim red light.
A 2022 randomized sham-controlled trial gave 26 people with MS either bright white light (10,000 lux) or dim red light (under 300 lux) as the inactive placebo. After the study, fatigue scores improved in both groups, but there was no significant difference between bright white light and the dim red sham (p = 0.136). A larger phase II trial published in the Journal of Neurology in 2020 used the same setup, bright white light versus dim red light, self-administered an hour at a time, twice a day.
Read that carefully. In these trials the researchers chose dim red light specifically because they expected it to do nothing. They used it as the fake treatment. The fact that fatigue improved in both groups is most likely a placebo effect, the natural lift people feel when they enroll in a study and take an active role in their care. None of this proves therapeutic red light is useless, because dim ambient red light at under 300 lux is nowhere near the dose a real therapy panel delivers. But it should make you skeptical of anyone who cites "light therapy improved MS fatigue" as proof that red light panels work.
The animal evidence is the strongest part, which is its own warning
The most encouraging data come from mice, not people. A 2024 systematic review and meta-analysis of PBM in animal models of MS, also in Frontiers in Neurology, pooled studies using a mouse model called EAE that mimics MS. Across the studies, PBM (mostly 660 to 670 nm) significantly reduced disease severity, with a mean clinical-score reduction of 1.44 (95% confidence interval -2.45 to -0.42, p = 0.006), and lowered markers of inflammation and demyelination.
That sounds great until you read the authors' own conclusion. They warned that "the paucity of studies and the high risk of bias in the included studies warrants further preclinical investigation before conducting human studies." When the scientists running the meta-analysis say the field is not even ready for proper human trials, that tells you exactly how preliminary this is. Mouse results famously fail to translate to people far more often than they succeed.
Why the studies disagree: dose, wavelength, and target
It is tempting to look at one negative fatigue trial and one positive muscle trial and conclude the science is hopelessly muddled. But there is a thread that helps make sense of it: the studies tested very different doses, wavelengths, and body targets, and in PBM research those details decide everything.
Consider what actually differed between the fatigue trial that failed and the muscle trial that partly worked:
- Dose. The fatigue study used a fixed 36 joules. The muscle study tested 40, 80, and 120 joules, and only the individualized, higher doses produced gains. PBM is famous for a "biphasic" dose response, where too little does nothing and too much can suppress the very effect you want. A single fixed dose may simply have missed the window.
- Wavelength. The fatigue study used 808 nm light alone. The animal studies that worked leaned on 660 to 670 nm red light, sometimes paired with near-infrared. Different wavelengths reach different tissue depths and may drive different cellular responses.
- Target. The fatigue study aimed light under the tongue and over a wrist artery, an indirect approach hoping for whole-body effects. The muscle study aimed light directly at the muscle being measured. Treating tissue you can actually reach is a far easier ask than expecting light at the wrist to fix brain-driven fatigue.
None of this rescues the fatigue claim. It does explain why a flat statement like "red light therapy works for MS" or "red light therapy does nothing for MS" is both wrong. The truthful version is narrower: certain doses of red and near-infrared light, aimed directly at muscle, may modestly help strength, while the parameters tried so far have not helped fatigue. The field has not landed on a standard protocol, and until it does, results will keep bouncing around.
Evidence Scorecard
Here is the bottom line on each claim, graded honestly by what the human data show.
| MS-related claim | What was tested | Direction of evidence | Honest grade |
|---|---|---|---|
| Reduces MS fatigue | PBM 808 nm, 36 J (pilot RCT) | No effect found | Weak / negative |
| "Light therapy" helps fatigue | Bright white vs dim red light | Improved equally in both arms (placebo-likely) | Not red-light specific |
| Improves muscle strength / force recovery | PBM 40–120 J, sham-controlled crossover | Significant gain vs sham | Promising but tiny |
| Improves muscle endurance / fatigue resistance | Same crossover study | No improvement | Weak / negative |
| Reduces inflammation and disease severity | EAE mice, meta-analysis | Significant reduction | Animal-only; authors urge caution |
| Slows MS progression / repairs myelin in people | Not tested in any human RCT | No human evidence | Unproven |
How Red Light Stacks Up Against Real MS Treatments
To keep expectations grounded, it helps to see where red light sits next to therapies that actually have approval and strong evidence.
| Approach | Evidence level for MS | What it targets | Status |
|---|---|---|---|
| Disease-modifying therapies (DMTs) | Strong; many FDA-approved | Slow relapses and disability progression | Standard of care |
| Exercise and physical therapy | Strong | Fatigue, strength, mood, mobility | Guideline-recommended |
| Cognitive behavioral therapy / energy management | Moderate to strong | Fatigue coping, mood | Recommended |
| Vitamin D, healthy diet | Moderate (supportive) | General disease support | Commonly advised |
| Red light therapy (PBM) | Weak and early | Muscle strength (maybe), inflammation (in mice) | Experimental |
| Bright white light therapy | Mixed; placebo-prone | Circadian fatigue | Experimental |
The takeaway is not that red light is a scam. It is that red light belongs in the "interesting, worth studying" column, not the "proven treatment" column. Nothing here should replace a neurologist or a prescribed DMT. The National MS Society's integrative medicine guidance takes the same stance: complementary approaches can sit alongside standard care, never in place of it. The federal NCCIH summary on MS and complementary approaches reaches a similar conclusion, noting that most non-drug options for MS have limited or low-quality evidence.
Is It Safe for People With MS?
Safety is the one area where red light therapy looks reassuring. Across the studies above, including the systematic review, no serious adverse effects were reported. PBM does not heat tissue meaningfully, does not use ionizing radiation, and is generally well tolerated. The bright-light fatigue trials likewise found the treatment "safe, feasible, and well-tolerated."
That said, MS brings specific cautions:
- Heat sensitivity (Uhthoff's phenomenon). Many people with MS feel worse when they overheat, even slightly. Quality red light panels run cool, but cheap or very high-power devices can warm the skin. Keep sessions short and watch for any temporary worsening of symptoms.
- Eye protection. Bright LED panels can be harsh on the eyes, and some MS patients have a history of optic neuritis. Wear the goggles that come with the device and do not stare into the light.
- Skin and medications. Some MS medications and other drugs increase light sensitivity. Ask your prescriber before starting.
- Heat-related fatigue. Because overheating can mimic or trigger MS fatigue, getting too warm during a session could backfire on the very symptom you are trying to treat.
For a fuller rundown that applies to any user, see our guide to red light therapy side effects and risks. The short version: low risk, but not zero, and MS adds a few wrinkles worth respecting.
Who Might Reasonably Consider It (and Who Shouldn't Bank On It)
It might be reasonable to try if you:
- Have mild-to-moderate MS and are mainly hoping for a modest boost in muscle strength or recovery, with realistic expectations.
- Already use it for another reason (skin, joint pain) and are simply curious whether it helps your MS symptoms.
- Understand it is experimental, are keeping your DMTs and physical therapy going, and have cleared it with your neurologist.
- Can tolerate heat well and will keep sessions short and cool.
You should not count on it if you:
- Are looking for fatigue relief as the main goal. The most direct fatigue trial found no benefit.
- Hope it will slow MS progression or repair nerve damage. No human study supports that.
- Are tempted to delay, reduce, or skip prescribed treatment in favor of light. That is the genuinely dangerous move.
- Have significant heat sensitivity and find that warming triggers your symptoms.
The mechanism overlaps with research in related neurological areas, such as photobiomodulation for traumatic brain injury, where the science is also promising but still maturing. MS is simply further behind, with fewer and smaller human trials.
Questions to Ask Before You Try It
If you decide red light therapy is worth a careful experiment, treat it like one. A few questions can keep you from wasting money or, worse, getting hurt.
For your neurologist:
- Are any of my current medications likely to make my skin or eyes more light-sensitive?
- Given my heat sensitivity, is regular light exposure a problem for me?
- If I try this, what symptom should I track, and how will we know if it is actually helping versus just placebo?
- Is there any reason this could interfere with my disease-modifying therapy? (Most evidence says no, but ask.)
For a studio or device seller:
- What wavelengths and irradiance does this device actually deliver, with measured numbers, not just marketing claims?
- How hot does the skin get during a typical session? (This matters more for MS than for most users.)
- What is your refund or trial policy if I see no benefit in four to six weeks?
- Are you making any claims about treating or curing MS? (If they say yes, walk away. No device is FDA-cleared to treat MS, and that claim is a red flag.)
The honest answer to "will this help my MS" is that you may not know without trying it and tracking carefully. That is exactly why an objective measure, like a timed walk or a grip-strength test, beats a vague sense of "I feel a bit better." Fatigue and well-being in MS swing day to day on their own, and the placebo effect in this condition is strong enough to fool both patients and researchers.
A reasonable trial period is four to six weeks of consistent use, with a baseline measurement before you start and the same measurement at the end. If nothing has budged, the responsible move is to stop spending money on it rather than convince yourself it must be working.
What Better Evidence Would Look Like
If you want to track whether red light therapy for MS graduates from "maybe" to "proven," watch for these:
- Larger trials. Studies with hundreds of participants, not a dozen or two.
- Active sham controls. Real placebo light that participants cannot tell apart from the treatment, to strip out the powerful placebo effect MS fatigue is prone to.
- Standardized dosing. Agreed-upon wavelengths, joules, and treatment sites. The current studies are all over the map, which is why their results cannot be compared cleanly.
- Objective outcomes. Not just questionnaires, but measurable changes in walking speed, strength, MRI lesions, or inflammatory markers.
- Replication. The same positive result repeated by an independent team.
Until several of those boxes are checked, the responsible framing stays the same: interesting, low-risk, unproven.
Frequently Asked Questions
Does red light therapy reduce MS fatigue?
The most direct human trial found it did not. A 2022 pilot study using an 808 nm laser at 36 joules reported no effect on fatigue in people with relapsing-remitting MS. Separate "light therapy" trials that did show fatigue improvement used bright white light, a different treatment, and even those improvements matched a dim red placebo, pointing to a placebo effect rather than a true benefit. So no, the evidence does not currently support red light therapy as a reliable fatigue treatment for MS.
Can red light therapy help with MS muscle weakness?
Possibly, in a limited way. One small, well-controlled 2024 study found that individualized doses of photobiomodulation improved muscle strength and force recovery in people with mild-to-moderate MS compared with a sham. But the same study found no improvement in muscle endurance, and the sample was very small. It is a promising signal, not a proven treatment, and it needs to be repeated in larger trials.
Is red light therapy safe for someone with multiple sclerosis?
It appears low-risk. No serious side effects were reported in the MS studies done so far. The main MS-specific cautions are heat sensitivity (avoid overheating, which can temporarily worsen symptoms), protecting your eyes especially if you have a history of optic neuritis, and checking with your doctor if you take medications that increase light sensitivity. Always clear it with your neurologist first.
Can red light therapy replace my MS medication?
No. There is no human evidence that red light therapy slows MS progression or repairs nerve damage, and nothing here should replace disease-modifying therapy or any prescribed treatment. Stopping your medication in favor of light therapy could allow the disease to advance. Treat red light as something you might add on, with your doctor's input, never as a substitute.
Why do some websites claim red light therapy works for MS?
Most of those claims lean on animal studies in mice or on bright-light fatigue trials that are not actually red light therapy. The mouse data do look encouraging, but the researchers who pooled them specifically warned that the field is not yet ready for confident human conclusions. When you separate the marketing from the human trials, the honest picture is early and mixed, not a clear win.
This article is for educational purposes only and is not medical advice. Talk to your neurologist or doctor before starting any new therapy for multiple sclerosis.